Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CDKN2C/p18 INK4c Double Nickase Plasmid (h): sc-401214-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CDKN2C/p18 INK4c Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CDKN2C/p18 INK4c Double Nickase Plasmid (h) and CDKN2C/p18 INK4c Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CDKN2C. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CDKN2C/p18 INK4c Antibody (118.2): sc-9965
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CDKN2C/p18 INK4c Double Nickase Plasmid (h) | sc-401214-NIC | 20 µg | $410.00 | |||
CDKN2C/p18 INK4c Double Nickase Plasmid (h2) | sc-401214-NIC-2 | 20 µg | $410.00 |
CDKN2C encodes p18INK4c, a cyclin-dependent kinase inhibitor that binds CDK4/6 to restrain Cyclin D–dependent kinase activity and enforce the G1/S cell-cycle checkpoint. By limiting phosphorylation of RB1 and downstream E2F transcriptional programs, CDKN2C contributes to proliferative control, cellular differentiation, and senescence-associated responses. Altered CDKN2C function or expression has been linked to dysregulated cell-cycle progression observed across multiple cancer contexts and hematologic malignancies, and it is frequently studied alongside other INK4 family regulators. CDKN2C is also relevant to pathways integrating mitogenic signaling with checkpoint control, including RB/E2F and CDK4/6 axis regulation.
CDKN2C/p18 INK4c Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CDKN2C locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CDKN2C. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CDKN2C function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CDKN2C-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.